Thanks to all who have contributed to the excellent discussion on the role of sequencing technology. It is clear that many patients are doing poorly due to unrecognised drug resistance as well as limited access to DR-TB drugs such as linezolid, bedaquiline and delamanid and other gaps in the DR-TB cascade of care. How should we approach patients with DR-TB who are currently failing therapy in terms of ongoing transmission?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.